[Therapeutic strategies for HIV infection: redefining simplification].
Simplifying therapeutic strategies against human immunodeficiency virus comes first in order to optimise the clinical benefit of long-term antiretroviral treatments for patients. The simplification of dosage and reduction of the number of antiretroviral classes used is expected by patients and physicians alike, as ease of use and reduced restraint improve compliance and quality of life. On the other hand, another priority for simplified treatments is a durable and strong efficacy, together with good tolerance and few long-term complication risks. Nevertheless, the simplification process must not neglect virologic efficacy objectives. Risks of crossed intra-class resistances in case of therapeutic failure must especially be taken intro account. Eventually, new ways of simplification such as NNRTI/boosted PI combinations or boosted PI alone deserve to be thoroughly explored by controlled randomised trials.